Commentary|Podcasts|September 7, 2025
Standardizing Gene Therapy Care in Duchenne: An Overview of Consensus Guidelines
Author(s)Barry Byrne, MD, PhD
Marco Meglio
Marco Meglio
Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Barry Byrne, MD, PhD.
Advertisement
Episode 149 of the NeurologyLive® Mind Moments ® is now live! Scroll down to listen or to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in neurology discussing the latest research and disease management strategies across the breadth of the field, including epilepsy, multiple sclerosis, Parkinson disease (PD), dementia, sleep disorders, and more.
In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, PhD, the chief medical advisor at the Muscular Dystrophy Association and the director of the Powell Gene Therapy Center at the University of Florida, speaks on the MDA and Parent Project Muscular Dystrophy's new consensus guidelines, which were recently published and cover safe delivery and monitoring practices for Duchenne muscular dystrophy (DMD) gene therapy. Byrne stressed the necessity of standardized practices for patient selection, administration, and follow-up care, especially as wider availability of gene therapy is dawning, which explain the rationale for bringing together a panel of experts from across the globe. Byrne also drew attention to the key role of expanded multidisciplinary teams with experts in hematology, cardiology, nephrology, and immunology, for the management of immune-related safety concerns. In particular, he pointed out that special attention need to be paid to liver inflammation monitoring and emerging strategies like the use of rapamycin. Furthermore, Byrne also went over geographic barriers, language considerations, and financial constraints—the real-world challenges surrounding access—and emphasized the role of these concerns in guiding the future of gene therapy approaches that continue to be developed.
The stories featured in this week's Neurology News Minute, which provide quick updates on the following developments in neurology, are further detailed here:
Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose
EPISODE BREAKDOWN
- 1:00 – Why consensus guidelines were needed for gene therapy in DMD
- 2:10 – Top-line clinical considerations from the published recommendations
- 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity
- 6:30 – Neurology News Network
- 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care
- 12:00 – How these recommendations may shape the future of DMD treatment
Hoping to listen on your favorite podcast app? See below:
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025
- CGTLive®’s Weekly Rewind – August 29, 2025
August 29th 2025
Advertisement
Advertisement